Syneos Health Consulting Releases Biopharma Dealmakers Survey

Published on: 

Pharmaceutical Executive

Syneos Health Consulting, a biopharmaceutical management consulting firm, released its 11th annual Dealmakers’ Intentions Study. The study indicates there will be an acceleration in dealmaking across all deal types and that buyers seem more willing to accept risk associated with opportunities in the early development and rare disease categories.

To view the study, visit here.